Literature DB >> 15328137

Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya.

Abigael Mbaisi1, Pamela Liyala, Fredrick Eyase, Rachel Achilla, Hosea Akala, Julia Wangui, Josphat Mwangi, Finnley Osuna, Uzma Alam, Bonnie L Smoak, Jon M Davis, Dennis E Kyle, Rodney L Coldren, Carl Mason, Norman C Waters.   

Abstract

The drug resistance profiles of Plasmodium falciparum isolated from four regions in Kenya were analyzed for drug resistance profiles. We observed variability in resistance to a broad range of antimalarial drugs across Kenya as determined from in vitro drug susceptibility screening and genotyping analysis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328137      PMCID： PMC514731          DOI： 10.1128/AAC.48.9.3598-3601.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  38 in total

1.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Authors:  James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

2.  The development of Lapdap, an affordable new treatment for malaria.

Authors:  Trudie Lang; Brian Greenwood
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

3.  Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance.

Authors:  Edward K Mberu; Alexis M Nzila; Eunice Nduati; Amanda Ross; Stephanie M Monks; Gilbert O Kokwaro; William M Watkins; Carol Hopkins Sibley
Journal:  Exp Parasitol       Date:  2002 Jun-Jul       Impact factor: 2.011

4.  Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment.

Authors:  J Curtis; C A Maxwell; F H M Msuya; S Mkongewa; A Alloueche; D C Warhurst
Journal:  J Infect Dis       Date:  2002-11-15       Impact factor: 5.226

Review 5.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?

Authors:  C H Sibley; J E Hyde; P F Sims; C V Plowe; J G Kublin; E K Mberu; A F Cowman; P A Winstanley; W M Watkins; A M Nzila
Journal:  Trends Parasitol       Date:  2001-12

6.  Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial.

Authors:  J Sulo; P Chimpeni; J Hatcher; J G Kublin; C V Plowe; M E Molyneux; K Marsh; T E Taylor; W M Watkins; P A Winstanley
Journal:  Lancet       Date:  2002-10-12       Impact factor: 79.321

Review 7.  Chloroquine-resistant malaria.

Authors:  T E Wellems; C V Plowe
Journal:  J Infect Dis       Date:  2001-08-07       Impact factor: 5.226

Review 8.  Epidemiology of drug-resistant malaria.

Authors:  Chansuda Wongsrichanalai; Amy L Pickard; Walther H Wernsdorfer; Steven R Meshnick
Journal:  Lancet Infect Dis       Date:  2002-04       Impact factor: 25.071

9.  Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya.

Authors:  J T Bousema; L C Gouagna; A M Meutstege; B E Okech; N I J Akim; J I Githure; J C Beier; R W Sauerwein
Journal:  Trop Med Int Health       Date:  2003-05       Impact factor: 2.622

10.  Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.

Authors:  Amar Bir Singh Sidhu; Dominik Verdier-Pinard; David A Fidock
Journal:  Science       Date:  2002-10-04       Impact factor: 47.728
View more
  17 in total

1.  Inhibitory activity of ferroquine, versus chloroquine, against western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay.

Authors:  Fredrick L Eyase; Hoseah M Akala; Jacob D Johnson; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.

Authors:  Jacob D Johnson; Richard A Dennull; Lucia Gerena; Miriam Lopez-Sanchez; Norma E Roncal; Norman C Waters
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

3.  Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.

Authors:  David J Bacon; Christine Latour; Carmen Lucas; Olga Colina; Pascal Ringwald; Stéphane Picot
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay.

Authors:  Edgie-Mark A Co; Richard A Dennull; Drew D Reinbold; Norman C Waters; Jacob D Johnson
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

5.  Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.

Authors:  Hoseah M Akala; Fredrick L Eyase; Agnes C Cheruiyot; Angela A Omondi; Bernhards R Ogutu; Norman C Waters; Jacob D Johnson; Mark E Polhemus; David C Schnabel; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

6.  Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.

Authors:  Vincent Jullien; Bernhards Ogutu; Elizabeth Juma; Gwenaelle Carn; Charles Obonyo; Jean-René Kiechel
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

7.  Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.

Authors:  Charlotte A Lanteri; Suwanna Chaorattanakawee; Chanthap Lon; David L Saunders; Wiriya Rutvisuttinunt; Kritsanai Yingyuen; Ian Bathurst; Xavier C Ding; Stuart D Tyner
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

8.  Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assay.

Authors:  Stuart D Tyner; Chanthap Lon; Youry Se; Delia Bethell; Doung Socheat; Harald Noedl; Darapiseth Sea; Wichai Satimai; Kurt Schaecher; Wiriya Rutvisuttinunt; Mark M Fukuda; Suwanna Chaorattanakawee; Kritsanai Yingyuen; Siratchana Sundrakes; Panjaporn Chaichana; Piyaporn Saingam; Nillawan Buathong; Sabaithip Sriwichai; Soklyda Chann; Ans Timmermans; David L Saunders; Douglas S Walsh
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

9.  Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya.

Authors:  Maroya D Spalding; Fredrick L Eyase; Hoseah M Akala; Sheryl A Bedno; Sean T Prigge; Rodney L Coldren; William J Moss; Norman C Waters
Journal:  Malar J       Date:  2010-11-24       Impact factor: 2.979

10.  The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.

Authors:  Fredrick L Eyase; Hoseah M Akala; Luiser Ingasia; Agnes Cheruiyot; Angela Omondi; Charles Okudo; Dennis Juma; Redemptah Yeda; Ben Andagalu; Elizabeth Wanja; Edwin Kamau; David Schnabel; Wallace Bulimo; Norman C Waters; Douglas S Walsh; Jacob D Johnson
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.